CBF and somatosensory evoked potentials (SEPs) were measured in a model of moderate cerebral ischemia in anesthetized spontaneously hypertensive rats. The rats were bled to reduce SEP amplitudes to about 50% of prebleeding control. The consequent blood pressure fall reduced CBF to 77% of control as measured by the laser-Doppler technique. Naloxone (5 mg kg -1 i. v. plus 25 mg kg -1 h -1 i. v. for 30 min) caused a significant increase in SEP amplitudes, while CBF did not change significantly. In addition, the latency of the first SEP component decreased toward prebleeding values. Heart rate (HR) decreased, but MABP was held constant by a pressure-regulating reservoir. In unbled rats, naloxone (5 Abbreviations used: fSEP, amplitude of the first SEP compo nent; GABA, -y-aminobutyrate; HR, heart rate; MeA, middle cerebral artery; SEP, somatosensory evoked potential; SHR, spontaneously hypertensive rat; sSEP, amplitude of the second SEP component.
In 1981 Baskin and Hosobuchi reported that nal oxone reversed neurological deficits in two patients suffering from cerebral ischemia and put forward the hypothesis that endogenous opioids play a ma jor role in the pathophysiology of cerebral ischemia and that opioid antagonists could be of therapeutic value. Since then this hypothesis has been tested in various experimental models of cerebral ischemia and stroke, as well as in humans, with conflicting results (see Faden, 1986) .
We have tested this hypothesis in a model of rel atively mild global ischemia where chloralose anesthetized spontaneously hypertensive rats (SHRs) were bled so as to induce an attenuation of somatosensory evoked potentials (SEPs) to 5�O% mg kg -1 i. v.) caused a transient small increase in MABP and SEP amplitudes and decrease in HR. These results indicate that sensory input is regulated by opioid systems. Increased opioid activity may inhibit ascending sensory pathways during relative cerebral ischemia and thereby depress SEP responses. Thus, naloxone can release this inhibition and enhances SEP independently of CBF dur ing relative cerebral ischemia. Similar mechanisms might explain the apparently beneficial effects of naloxone in some stroke models. Key Words: Cerebral blood flow Cerebral function-Cerebral ischemia-Endogenous opi oids-Hemorrhage-Naloxone-Somatosensory evoked potentials-Spontaneously hypertensive rats.
of control under constant control of blood pressure and CBF (Skarphedinsson et aI., 1986 (Skarphedinsson et aI., , 1989 . In this model, the opioid antagonists naloxone and Win 44.441-3 stereospecifically improved cerebral func tion as measured by SEPs, despite the fact that ar terial pressure was kept constant at a hypotensive level Thoren, 1986, 1988) .
The important question then arises: By what mechanism do opioid antagonists improve SEPs in our model? Many explanations can be suggested.
An obvious one is improved metabolic status by increased CBF, for example, by a direct vasodilator effect on cerebral vessels (Turner et aI., 1984a,b) , or indirect effects via decreased sympathetic activ ity Skarphedins son et aI., 1989) .
It is known from the studies of Harper et ai. (1972) and Fitch et ai. (1975) that at arterial pressure below the lower autoregulatory limit, sympathetic activity to the circle of Willis and large cerebral arteries can have a great effect on total cerebrovas cular resistance and thus CBF. In our previous studies on the effects of opioid antagonists, we did not measure CBF. Because of the obvious parallel-ism between changes in heart rate (HR), renal sym pathetic activity, and cerebrovascular resistance during hemorrhage in SHRs (Skarphedinsson et al., , 1989 , it is possible that sympathetic activity to large cerebral arteries shows similar changes and therefore may increase cerebrovascular resistance.
Further, when the opioid antagonists induce brady cardia and reduce renal sympathetic activity (Skar phedinsson and Thoren, 1986), similar changes in cerebrovascular resistance might occur, increasing CBF and, secondary to this, improving cerebral function.
The aim of this investigation was therefore to study changes in cortical blood flow directly as well as cerebral function during naloxone infusion in SHRs exposed to relative cerebral ischemia. We also studied the effects of naloxone on SEPs in un bled SHRs. Our data strongly speak against CBF changes as a major explanation for the improve ment of cerebral function when naloxone is infused during relative cerebral ischemia.
METHODS

Surgical preparation
Adult male SHRs (250-350 g; Mollegaard Breeding Center, Denmark) were used. The rats were initially anes thetized with methohexital sodium (70 mg kg-t i.p. Bri etal; Lilly, Indianapolis, IN, U.S.A.), tracheotomized, and prepared with catheters in the tail artery (PE-25) for arterial pressure recording, the right jugular vein (PE-25) for intravenous injections, and the right iliac artery (PE-90) for hemorrhage. The rats also received a bolus of a-chloralose [50 mg kg-t i.v.; a solution of 25 mg ml-I chloralose and 50 mg ml-I NazB407 (borax)] followed by a continuous chloralose infusion (40 mg kg -1 h -I; a so lution containing 8 mg ml-1 chloralose, 16 mg ml-1 Na2B407, and 6 mg ml-I NaCI; infusion rate 4.5 ml kg-I h -1 through a side branch of the tail artery catheter). Rectal temperature was continuously monitored and maintained at 37SC by external heating.
Arterial pressure was measured from the tail artery with a Statham 23DC pressure transducer. HR was mea sured from the pulsating arterial pressure signal with a rate meter, and MABP obtained by electronic filtering. The variables were recorded on a Grass polygraph and also fed to a microcomputer that recorded the mean signal levels during loo-s intervals every other minute.
The methods for SEP recordings have been described in detail elsewhere (Skarphedinsson et aI., 1986) . Briefly, two brass screws were fixed in two small burr holes in the exposed skull, one over the left somatosensory area and the other on the midline just behind the lambda. EEG was recorded from the screws (0.5-700 Hz, -3 db), amplified, and fed to the computer. The computer averaged 50 sweeps of 300 ms after a stimulus was applied (at 2-s intervals) via a small tactile stimulator fixed to the vibris sal area on the right side of the snout (vibrissae cut). The averaged complex was analyzed by the computer by de fining the pI, nl, p2, and n2 peaks and the pl-nl and p2-n2 amplitudes defined as the first and second SEP J Cereb Blood Flow Metab, Vol. 9, No.4, 1989 components (fSEP and sSEP, respectively). The latency of the first positive peak pi was also measured. This peak corresponds to the N201P20 obtained in humans (Allison and Hume, 1981) . The averaged complex was then re corded on the polygraph, thus giving a display of the SEP at 2-min intervals.
The method for CBF recordings with the laser-Doppler technique is described in detail by . Briefly, the rat's head was fixed in a head holder. The skull bone and dura mater over the right somatosen sory area were removed from an area of 4 x 4 mm with its center -2 mm behind the bregma and 5 mm lateral to the sagittal suture.
The laser velocimetry was performed by means of a Peri Flux PF2 laser-Doppler flowmeter (2 mW, wave length 632.8 nm, frequency range 20-12,000 Hz, PF-103 probe; Perimed KB, Stockholm, Sweden). The probe (held in a micromanipulator) was placed vertically to the cortical surface, with the probe tip 1.0 mm above the surface. The exposed cortex was then covered with phys iological saline-agar, also filling up the gap between the laser probe and the cortical surface. The agar was then covered with a rubber impression material (Permlastic light body polysulfide; Kerr GmbH, Karlsruhe, F.R.G.).
The flux signal from the laser velocimeter (CBF) was recorded on the polygraph with a time constant of 1.5 s and also fed into the computer and handled the same way as the MABP and HR signals. The postmortem signal was considered as baseline (0%) and subtracted from CBF values, and the mean values during a 6-min period just before hemorrhage set as 100%.
In addition, 10 rats were prepared for the MABP and SEP recordings only; i.e., they were subjected neither to iliac artery catheterization nor to head operation for CBF recordings.
Experimental procedure
After completion of the surgical preparation, 1 h was allowed for stabilization with no additional methohexital before control measurements were made.
Ischemic group. Twelve rats were heparinized (100 IU 100 g-I heparin; Lovens, Malmo, Sweden) and control measurements made for 30 min. These rats were then bled by connecting the iliac artery catheter to a pressur ized reservoir, which pressure was then lowered to -45 mm Hg. This resulted in a pressure-controlled hemor rhage, maintaining MABP at the reservoir pressure. This low pressure was maintained until the fSEP amplitude had attenuated to -50% of control. To prevent disappearance of SEPs, MABP was then raised to 60-70 mm Hg by retransfusion. Then, if fSEPs recovered to a level higher than 60% of control, MABP was lowered a few millime ters of mercury to keep fSEP at a level below 60% of control. Rats in which unpredictable large fluctuations of SEPs were seen after the retransfusions were excluded from the study.
When a constant MABP had been maintained for 15 min after the retransfusion (to ascertain that SEP was not increasing spontaneously), 5 mg kg-I i.v. naloxone (Sigma, St. Louis, MO, U.S.A.) in 0.05 ml saline was administered as a bolus, and a 30-min continuous infusion of 25 mg kg-I h -\ i. v. started. MABP was kept constant by the pressure-regulating reservoir. After the infusion was discontinued, the animals were followed for an addi tional 30 min.
Unbled group. These rats (n = 10) were not bled and CBF was not recorded. After a 3D-min control period, they received a bolus injection of naloxone 5 mg kg-1 in 0.05 ml saline i. v.
Statistical analysis
All results are given as means ± SE. Changes in HR, CBF, fSEP, sSEP, and latency between prehemorrhage control and prenaloxone control were tested with Stu dent's t test for paired observations. Naloxone effects (0-60 min in the ischemic group and (}-14 min in the un bled group) were subjected to analysis of variance for repeated measurements, followed by Dunnett's test where postnaloxone values were compared with pre naloxone control values (0 min). p < 0.05 was regarded as significant.
RESULTS
Ischemic group
The results from the bled rats are presented in Figs. 1-3. The rats responded to the hypotension as The effects of naloxone on mean arterial pressure, heart rate (HR), and CBF in bled spontaneously hypertensive rats. Naloxone (5 mg kg-1 ) was injected at a min, and an infusion (25 mg kg -1 h -1) continued for 30 min. Means ± SE.
Significance of change in HR and CBF was tested with Dun nett's test, comparing postnaloxone values with a prenalox one control value (0 min). Significance is indicated with sym bols: *p < 0.05, **p < 0.01. described in previous reports (Skarphedinsson et aI., 1986 (Skarphedinsson et aI., , 1989 . HR showed the characteristic bradycardic-tachycardic response, being 352. 5 ± 4.7 beats min -) before hemorrhage, but 372. 5 ± 11.1 beats min -) just before naloxone injection (p = 0.079). CBF decreased upon hemorrhage to lev els � 25% lower than control and tended to decrease further during the tachycardic phase. The lowest mean CBF was recorded after 42 min of hemor rhage, 70.6 ± 6.0% of control. The partial retrans fusion increased CBF slightly, and when naloxone was injected, it was at 77.4 ± 4.0% of control (p < 0.001). Naloxone was administered after a hypoten sion period of 68 ± 7 min. fSEP and sSEP had then attenuated to 40.2 ± 3.0% (p < 0. 001) and 47.6 ± 8.4% (p = 0.0016) of control, respectively. The fSEP latency had increased from 7.8 ± 0.9 to 14.6 ± 1.2 ms (p < 0.001). Naloxone significantly in creased the amplitude of both fSEP and sSEP (Figs. 2 and 3) and decreased the fSEP latency (Fig. 2) .
HR decreased while CBF was not significantly af fected (Fig. 1) .
Unbled rats
Results from the unbled rats are shown in Fig. 4 .
Naloxone caused small but significant increases in SEP amplitudes and MABP. HR decreased tran siently, while the fSEP latency was not affected (not shown).
DISCUSSION
The main finding in this study is that naloxone in the present experimental situation does not change CBF despite a marked rise in SEP responses in ischemic SHRs. This lack of any effect on CBF is surprising. Our previous observations of parallel in creases of HR and renal sympathetic nerve activity and HR and cerebrovascular resistance during late hemorrhage suggested that sympathetic outflow to the circle of Willis and large cerebral arteries would also increase and thus the increased cerebrovascu lar resistance (Skarphedinsson et aI., 1986 (Skarphedinsson et aI., , 1989 . Much of the discrepancy is probably related to such factors as differences in methods, species, and pres ence and type of anesthesia (Holaday, 1983) . Mor phine and opioid peptides have been found to change CBF, but the changes can often be related to secondary effects of changes in metabolic rate, sys temic hemodynamic parameters, or respiration and PaCOZ (Sokoloff, 1959; Takeshita et aI., 1972; Koskinen and Bill, 1983; Matsumya and Dohi, 1983; Buchweitz et aI., 1984; Blum et aI., 1985; Sandor et aI., 1986a) . Pial vessels have been found to dilate in response to opiate-like substances (Hanko and Hardebo, 1978; Sandor et al., 1983; Kobari et aI., 1985) , although this was not observed in other ex periments (Wahl, 1982) . A recent study by Sandor et ai. (1986a) receptor antagonists have been found either to have no effect on CBF (Koskinen and Bill, 1983; Sandor et aI., 1986a) or to decrease (Takeshita et aI., 1972; Grandison et aI., 1982; Turcani et aI., 1986) or in crease (Turner et aI., 1984a, b; Phillis et aI., 1985) CBF. In the study of Sandor et al. (1986a) , nalox one was found to abolish CBF autoregulation, and the studies of Turner et al. indicate that naloxone has unspecific direct dilatatory effects on cerebral vessels (Sasaki et al., 1984a,b; Turner et al., 1984a,b) , although it was ineffective during high dose barbiturate anesthesia (Turner et aI., 1984c) . 1984) found no effect of naloxone on basilar artery diameter. Furthermore, after MCA occlusion in monkeys, Gaines et aI. (1984) found no effect of naloxone on CBF, infarct size, or neurological func tion. Thus, when taken together, these studies rather indicate that naloxone can improve cerebral function independently of changes in CBF, and our results from the present study support this.
Several observations indicate that opioid antago nists may have effects on metabolism that could be favorable during cerebral ischemia. Thus, brain ox ygen consumption has been found to decrease after naloxone (Takeshita et aI., 1972; Grandison et aI., 1982) . Direct metabolic effects of naloxone include inhibition of proteolysis and stabilization of lysoso mal membranes (Curtis and Lefer, 1980) , inhibition of lipid peroxidation (Koft!h et aI., 1981; Marzullo and Hine, 1981) , and influences on cyclic adenosine monophosphate (Collier and Roy, 1974; Christie Pope et aI., 1986) and Na + , K + -ATPase (Christie Pope et aI., 1986). Ca 2+ fluxes may be affected by naloxone (Guerrero-Munoz et aI., 1979; Stokes et aI., 1984) , as well as platelet aggregation (Turcani et aI., 1986) . In addition, naloxone in high doses may antagonize excitatory amino acids (Kim et aI., 1987) . Khachaturian et aI., 1985) . In addition, dynorphin, a K-agonist, has been found to induce paraplegia in rats (Faden and Jacobs, 1983) and the high doses of naloxone needed for beneficial effects in cerebral ischaemic models suggest K-mediated effects.
Our results may thus indicate that hypotensive hemorrhage-induced cerebral ischemia results in opioid-mediated depression of sensory input result ing in depressed SEPs, which can be reversed by naloxone injection. Also, the rapid onset of the nal oxone effects on SEP in our studies supports this.
Evidence that similar mechanisms may lie behind beneficial effects of naloxone on motor function during cerebral ischemia comes from studies by Levy et al. (1982) , who observed an increased glu cose metabolic rate in subcortical structures impor tant in the regulation of motor function.
There is also evidence for an unspecific interfer ence of naloxone with ,),-aminobutyrate (GABA) ergic transmission (Dingledine et aI., 1978) . In an other study, we tested the effects of the GABA re ceptor antagonist bicuculline and did not find significant effects on SEP. In addition, effects of naloxone and another opioid receptor antagonist, Win 44.441-3, were found to be stereospecific con cerning SEP .
Although naloxone has been found to improve survival in some studies, it has never been found to induce significant histological changes indicative of neuronal sparing effects, i.e., decreased infarct size, regardless of whether postive effects on neu rological deficits were obtained (Zabramski et aI., 1984, Baskin et aI., 1986) or not (Hubbard and Sundt, 1983; Gaines et aI., 1984) . Transient benefi cial effects of naloxone on neurological deficits in cerebral ischemia may thus indicate only the pres ence of endorphinergic depression of viable neuro nal function and merely a better prognosis, as has been suggested by Estanol et al. (1985) and Handa et al. (1985) .
In conclusion, naloxone had no effect on moder ately reduced CBF, while a rapid improvement of cerebral function was obtained with naloxone. The SEP enhancement upon naloxone injection was also seen in unbled rats, suggesting that this sensory mo dality may be tonically controlled by endogenous opioid systems in normal situations. The attenua tion of SEP upon hemorrhage may be caused by accentuated activity in these more or less tonically active systems.
